DEF 14A of Omnicell, Inc., Apr 13, 2026

DEF 14A of Omnicell, Inc.

Filed Apr 13, 2026 · FY20250001104659-26-042631

Open on EDGAR

  1. PROXY STATEMENT FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 19, 2026

    | | Page | | Option Exercises and Stock Vested | 46 | | Severance and Change of Control Arrangements | 46 | | Potential Payments Upon Termination or Change of Control | 50 | | Risk Analysis of Our Compensation Plans | 51 | | CEO Pay Ratio | 51 | | Timing of Grant of Certain Equity Awards | 52 | | Pay Versus Performance | 52 | | EQUITY PLAN INFORMATION | 57 | | PROPOSAL NO. 3: APPROVAL OF 2009 EQUITY INCENTIVE PLAN, AS AMENDED | 57 | | Equity Compensation Plan Information | 70 | | STOCK OWNERSHIP | 71 | | Security Ownership of Certain Beneficial Owners and Management | 71 | | Delinquent Section 16(a) Reports | 72 | | CERTIFICATE OF INCORPORATION AMENDMENT | 73 | | PROPOSAL NO. 4: Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to provide exculpation from personal liability for certain officers as permitted by Delaware law and make certain other minor, non-substantive updates | 73 | | AUDIT MATTERS | | | PROPOSAL NO. 5: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 75 | | Report of the Audit Committee of the Board of Directors | 76 | | ADDITIONAL INFORMATION | 77 | | Householding Of Proxy Materials | 77 | | Other Matters | 77 | | APPENDIX A: 2009 EQUITY INCENTIVE PLAN | A-1 | | APPENDIX B: AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OMNICELL, INC. | B-1 |

  2. PROPOSAL NO. 1: ELECTION OF DIRECTORS

    PROPOSAL NO. 1: ELECTION OF DIRECTORS Omnicell’s Board presently has nine members. The Board members are divided into three classes, each with a three-year term: Class I, with a term expiring at the Annual Meeting; Class II, with a term expiring in 2027; and Class III, with a term expiring in 2028. The three directors currently serving in Class I, the class whose term of office expires at the Annual Meeting, have been nominated for re-election at the Annual Meeting: Joanne B. Bauer and Robin G. Seim, each of whom was previously elected by our stockholders and Eileen J. Voynick, who was elected to the Board in January 2024. If elected at the Annual Meeting, each of these three nominees would serve until the 2029 Annual Meeting of Stockholders and until his or her successor is elected and has qualified, or, if sooner, until the director’s death, resignation or removal. Although directors are elected by a plurality of votes, it is our policy that any nominee for director in an uncontested election who receives a greater number of votes “withheld” from his or her election than votes “for” such election shall submit his or her offer of resignation for consideration by the Corporate Governance Committee, which will then consider all of the relevant facts and circumstances and recommend to our Board the action to be taken with respect to such offer of resignation. Our Board will then act on our Corporate Governance Committee’s recommendation within ninety days following certification of the stockholder vote. Promptly following our Board’s decision, we will disclose that decision and an explanation of such decision in a filing with the Securities and Exchange Commission (“SEC”) or a press release. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors (unless the Board determines by resolution that any such vacancies will be filled by stockholders). A director elected by the Board to fill a vacancy in a class, including a vacancy created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is elected and qualified. It is the Company’s policy to encourage directors and nominees for director to attend the Company’s Annual Meeting of Stockholders. All our nine then-current directors attended our 2025 Annual Meeting of Stockholders. Our Corporate Governance Committee seeks to assemble a Board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise and management experience necessary to oversee and direct the Company’s business. To that end, the Corporate Governance Committee has evaluated the current directors in the broader context of the Board’s overall composition. The Corporate Governance Committee maintains a goal of recruiting directors who complement and strengthen the skills of other directors and who also exhibit integrity, collegiality, sound business judgment and other qualities that the Corporate Governance Committee views as critical to effective functioning of the Board. For information about the director nominees and each director whose term is continuing after the Annual Meeting, including information regarding the specific and particular experience, qualifications, attributes or skills of each director nominee and continuing director that led the Corporate Governance Committee to believe that such individuals should serve on the Board, please refer to the section below entitled “Information about our Directors and Nominees.” THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH NAMED NOMINEE. INFORMATION ABOUT OUR DIRECTORS AND NOMINEES. The following tables and the brief biographies that follow provide information, as of the date of this proxy statement, about each director nominee and each continuing director.

  3. PROPOSAL NO. 1: ELECTION OF DIRECTORS

    | | Age | Position(s) within Omnicell | Director Since | Class | Current Term Expires | Independent | Current Committee Membership | | | | | | | | | | | | Audit(1) | Comp. | Corp. Gov.(1) | M&A | | Director Nominees | | | | | | | | | | | | Joanne B. Bauer | 70 | Lead Independent Director | 2014 | I | 2026 | Yes | | X | | | | Robin G. Seim | 66 | Director | 2019 | I | 2026 | Yes | Chair | | | X | | Eileen J. Voynick | 71 | Director | 2024 | I | 2026 | Yes | | X | X | X | | Continuing Directors | | | | | | | | | | | | Randall A. Lipps | 68 | President, Chief Executive Officer and Chairman of the Board | 1992 | II | 2027 | No | | | | | | Mark W. Parrish | 70 | Director | 2013 | II | 2027 | Yes | X | X | | | | Kaushik “Bobby” Ghoshal | 57 | Director | 2023 | II | 2027 | Yes | | | X | X | | Edward P. Bousa | 67 | Director | 2021 | III | 2028 | Yes | X | | | Chair | | Bruce E. Scott | 70 | Director | 2019 | III | 2028 | Yes | X | | Chair | X | | Mary A. Garrett | 67 | Director | 2022 | III | 2028 | Yes | | Chair | X | |

  4. PROPOSAL NO. 1: ELECTION OF DIRECTORS

    (1) The Board approved the following changes to the Company’s committee membership, to be effective following the Annual Meeting: (a) Mr. Ghoshal will become a member of the Audit Committee; (b) Mr. Scott will step down as a member of the Audit Committee and (c) Mr. Ghoshal will step down from the Corporate Governance Committee. As reflected below, our three director nominees and six continuing directors exhibit a range of skills, experience, industry and professional background, tenure and perspectives that we believe enhance the Board’s ability to effectively fulfill its oversight responsibilities.

  5. Diversity of Experience

    Diversity of Experience The following graphics represent certain characteristics of our continuing directors and nominees.

  6. Diversity of Experience

    | Diversity of Tenure Balanced tenure is reflective of thoughtful refreshment | Independence 89% of directors are independent | | | |

  7. Director Nominees

    Director Nominees

  8. Class I Nominees for Election for a Three-Year Term Expiring at the 2028 Annual Meeting of Stockholders

    Class I Nominees for Election for a Three-Year Term Expiring at the 2028 Annual Meeting of Stockholders

  9. Joanne B. Bauer

    Joanne B. Bauer Joanne B. Bauer, age 70, has served as a director of Omnicell since January 2014. Since October 2013, Ms. Bauer has served as a Director of Advocate Health Inc. (and its predecessors Aurora Healthcare and Advocate Aurora Health), an integrated not-for-profit healthcare provider serving communities throughout eastern Wisconsin, northern Illinois, North Carolina and Georgia. From October 2001 until June 2014, Ms. Bauer served as President of Global Health Care at Kimberly-Clark Corporation, a global consumer packaged goods company. Ms. Bauer joined Kimberly-Clark in 1981 and held various marketing and management positions within its adult care and health care businesses. Ms. Bauer received a B.A. degree from Lawrence University and an M.B.A. from the University of Wisconsin, Oshkosh. The Corporate Governance Committee believes Ms. Bauer’s leadership and management in the healthcare industry, including serving as the president of the healthcare segment of a large multinational corporation and in various management and marketing roles, provide the Board with valuable insight regarding the healthcare industry.

  10. Robin G. Seim

    Robin G. Seim Robin G. Seim, age 66, has served as a director of Omnicell since March 2019. Mr. Seim initially joined Omnicell in January 2006 and served in various financial and operational leadership roles, including Chief Financial Officer from January 2006 to August 2015 and President of Global Automation and Medication Adherence from March 2016 until his retirement in March 2019. Prior to joining Omnicell, Mr. Seim served as Chief Financial Officer of several technology companies, including Villa Montage Systems, Inc. from 1999 to 2001, Candera, Inc. from 2001 to 2004 and Mirra, Inc., in 2005. Prior to 1999, Mr. Seim held a number of management positions with Nortel Networks, Bay Networks and IBM. Mr. Seim received a B.S. in accounting from California State University, Sacramento. The Corporate Governance Committee believes Mr. Seim brings to the Board a deep understanding of the Company’s financial and business operations and the healthcare industry, gained through his 13 years of experience as an executive officer of Omnicell in various financial and operational leadership roles. The Corporate Governance Committee believes that Mr. Seim’s extensive knowledge of the Company and its industry, combined with his prior financial expertise and leadership experience, provide the Board with invaluable insights into the Company’s financial and business operations, the healthcare industry, as well as financial and operational matters generally.

  11. Eileen J. Voynick

    Eileen J. Voynick Eileen J. Voynick, age 71, has served as a director of Omnicell since January 2024. Ms. Voynick served as Chief Executive Officer of Sparta Systems, a leading provider of enterprise-quality management software solutions, from July 2011 to April 2018. Prior to joining Sparta Systems, she served as the Chief Operating Officer at Allscripts from 2009 until 2011. From 2007 until 2009, she served as Executive Vice President of global sales, services, and support at Misys. Ms. Voynick served in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba and Accenture from 1994 until 2007. She served as a director at AdvancedMD from March 2016 to September 2018, as a member of the Board of Trustees and Executive Committee of Jefferson Health from 2017 to July 2020, as the Chair of the Board of Trustees of Philadelphia University from 2013 to July 2017, as a member of the Board of Trustees of Thomas Jefferson University from 2017 to July 2020 and as Chair of the Jefferson Academic Board of the Thomas Jefferson University from 2017 to 2019. Ms. Voynick previously served as Board Chair of AGS Health, a revenue cycle management provider, from April 2021 until August 2025. Ms. Voynick formerly served on the board of directors of Skydeck Acquisition Corp., a special purpose acquisition company, from April 2021 until April 2023, CDK Global, Inc., a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation and heavy equipment industries from June 2016 until July 2022 and r3, an enterprise blockchain technology company from June 2018 until June 2023. Ms. Voynick holds a B.S. in finance from Philadelphia University. The Corporate Governance Committee believes Ms. Voynick’s extensive leadership and management experience in the healthcare and technology industry, including serving as chief executive officer of an enterprise-quality management software solutions provider and chief operating officer of a medication management solutions, as well as other management roles, provides the Board with valuable insight regarding the healthcare industry.

  12. Continuing Directors

    Continuing Directors

  13. Class II Directors Continuing in Office Until the 2027 Annual Meeting of Stockholders

    Class II Directors Continuing in Office Until the 2027 Annual Meeting of Stockholders

  14. Randall A. Lipps

    Randall A. Lipps Randall A. Lipps, age 68, has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps served as a member of the Board of Trustees of the American Nurses Foundation from April 2019 until June 2025. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University. The Corporate Governance Committee believes Mr. Lipps’ extensive knowledge of the Company, including his founding of the Company and his nearly three decades of leading the Company as the President and CEO, provide the Board with invaluable current knowledge of the Company and extensive knowledge of the industry’s needs for improvements in healthcare economics and patient safety. In addition, his role in the operations of the Company provides the Board with a practical understanding of the issues and opportunities facing the Company.

  15. Mark W. Parrish

    Mark W. Parrish Mark W. Parrish, age 70, has served as a director of Omnicell since January 2013. Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, from 2008 to August 2018, and as Executive Chairman of TridentUSA Health Service from August 2018 to September 2019. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director and Vice Chairman of Viatris, Inc. (formerly, Mylan N.V.), a global pharmaceutical company, as the Chairman of Safecor, a privately held hospital services firm. He also served as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies from 2013 until May 31, 2025. Mr. Parrish received a B.A. from the University of California, Berkeley. The Corporate Governance Committee believes Mr. Parrish’s extensive leadership experience in the healthcare industry, including serving as the chairman and chief executive officer of a multi-service provider in the long-term care market and various other management roles, provides the Board with valuable insight regarding the healthcare industry and, specifically, the long-term care market.

  16. Kaushik “Bobby” Ghoshal

    Kaushik “Bobby” Ghoshal Kaushik “Bobby” Ghoshal, age 57, has served as a director of Omnicell since July 2023. He currently serves as Chief Executive Officer of Experity, Inc. (“Experity”), a leading software and services company for on-demand healthcare in the U.S. urgent care market, and previously served as President of Experity from August 2025 until February 2026. Prior to this, he served as the Chief Commercial Officer, SaaS of ResMed Inc. (“ResMed”), a global leader in digital health and cloud-connected medical devices from December 2023 until August 2025 and previously as President — SaaS Business from August 2021 to December 2023, and served as Chief Technology Officer of ResMed, from April 2018 until August 2021. Prior to that, Mr. Ghoshal served as Chief Operating Officer for Brightree LLC, a ResMed-owned provider of cloud-based SaaS for out-of-hospital care from June 2016 until April 2018. From 2012 until 2016, Mr. Ghoshal served as ResMed’s Vice President, Information Technology. Prior to 2012, Mr. Ghoshal held a number of technology management positions with Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Mr. Ghoshal holds an M.B.A. from Arizona State University and a B.S. degree in electronics engineering and telecommunications from the National Institute of Technology in Calicut, India. The Corporate Governance Committee believes Mr. Ghoshal’s extensive leadership experience in the healthcare and technology industries, including digital health and cloud computing, provides the Board with valuable expertise, particularly with respect to software products, digital and business transformation, information security, data analytics and artificial intelligence and machine learning. In addition, the Corporate Governance Committee considers Mr. Ghoshal’s business leadership experience to be an important asset to the Board.

  17. Class III Directors Continuing in Office Until the 2028 Annual Meeting of Stockholders

    Class III Directors Continuing in Office Until the 2028 Annual Meeting of Stockholders

  18. Edward P. Bousa

    Edward P. Bousa Edward P. Bousa, age 67, has served as a director of Omnicell since July 2021. He was a partner at Wellington Management Company LLC, an investment management firm, from 2005 until June 2020. Prior to that, Mr. Bousa held positions of increasing responsibility upon joining Wellington Management Company LLC in April 2000. Mr. Bousa was a mutual fund manager at Putnam Investments, LLC from 1992 to 2000. From 1983 to 1992, he was an equity research analyst and portfolio manager at Fidelity Investments, Inc. Mr. Bousa began his career as a commodity merchandiser at Louis Dreyfus Corporation from 1980 to 1982. Mr. Bousa is a Chartered Financial Analyst. He has also served as a director of Corebridge Financial, Inc., one of the largest providers of retirement solutions and insurance products in the United States, since August 2024, including as a member of the Audit Committee and has served as a member of its Compensation Committee since March 2025. He has also served as a director of Gartner, Inc., a leading Information Technology research and advisory company, since January 2026, including as a member of the Audit Committee. Mr. Bousa previously served as a director of Azenta, Inc., a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry, from January 2024 until January 2025, and was a member of the Audit and Environmental, Social and Governance Committees. He received a B.A. in economics from Williams College and an M.B.A. from the Harvard Business School. The Corporate Governance Committee believes Mr. Bousa’s extensive background and experience working with financial institutions through the capital markets brings valuable expertise to the Board. In addition, the Corporate Governance Committee considers Mr. Bousa’s financial and leadership skills and managerial roles, as well as his background and experience as an investment professional to be important assets to the Board.

  19. Bruce E. Scott

    Bruce E. Scott Bruce E. Scott, age 70, has served as a director of Omnicell since May 2019. From April 2014 to November 2018, Mr. Scott served as President of the EnvisionPharmacies division of EnvisonRxOptions, a healthcare and pharmacy benefit management company and a subsidiary of the Rite Aid Corporation. From September 2008 to April 2012, Mr. Scott held various executive roles at Medco Health Solutions, Inc., a pharmacy benefit management company, including President of Accredo Infusion Services, President of Critical Care Systems and Senior Vice President and Chief Pharmacist. From 2004 to July 2008, Mr. Scott was Chief Operating Officer of McKesson Medication Management LLC, a provider of pharmacy management services. Previously, he held several senior leadership roles at Allina Hospitals and Clinics, including as the Director of Pharmacy of United Hospital from 1987 to 1998. Mr. Scott currently serves on the University of Wisconsin, School of Pharmacy Board of Visitors, an advisory board for the School of Pharmacy and previously served as Chair from 2020 until 2024. Mr. Scott received a B.S. in pharmacy from the University of Wisconsin and an M.S. in pharmacy administration from the University of Kansas where he also completed a pharmacy residency program. The Corporate Governance Committee believes Mr. Scott’s leadership and management in the healthcare industry, and his extensive background and experience with pharmacy benefit management and healthcare payers in particular, provide the Board with valuable insight regarding the healthcare industry in general, as well as the internal operations and needs of our pharmacy customers.

  20. Mary A. Garrett

    Mary A. Garrett Mary A. Garrett, age 67, has served as a director of Omnicell since May 2022. Ms. Garrett is currently the President of M. Power Coaching and Consulting, LLC, a firm focused on developing executive leaders and helping organizations align brand and culture, customer experience and employee engagement for positive impact on business vitality and growth. Ms. Garrett has held this position since June 2018. From September 2008 until December 2015, Ms. Garrett served as the chief marketing officer, global markets at International Business Machines Corporation (“IBM”), a leading global provider of technology products and services. Prior to that, Ms. Garrett served in key positions of increasing authority and responsibility upon joining IBM in 1981 through August 2008. Ms. Garrett currently serves as a director of PROCEPT BioRobotics Corp., a surgical robotics company, and has served on the board of this company and as chair of its nominating and governance committee since December 2021. Ms. Garrett previously served as a director of Ethan Allen Interiors, Inc., a leading interior design company, manufacturer and retailer in the home furnishings marketplace, from January 2016 until November 2021, and was a member of the Audit Committee. She has also served as a director of Hillrom Corporation (subsequently acquired by Baxter International, Inc.), a global medical technology company, from March 2017 until December 2021, and was chair of the Nominating/Corporate Governance Committee and a member of the Audit Committee. Ms. Garrett received a B.S. in bio-medical engineering from Boston University and an M.S. in bio-electrical engineering from Brown University. The Corporate Governance Committee believes Ms. Garrett’s extensive background and experience in the technology industry, including digital transformation, big data and cognitive analytics, cybersecurity and cloud computing, provides the Board with valuable expertise. In addition, the Corporate Governance Committee considers Ms. Garrett’s marketing expertise and business leadership experience, as well as her broad international background, to be important assets to the Board.

  21. DIRECTOR COMPENSATION

    DIRECTOR COMPENSATION We believe it is essential for our long-term success to attract highly talented candidates for our Board. Commensurate with this philosophy, the Board compensates its non-employee directors with long-term equity-based compensation and a cash fee on a quarterly basis. In determining the number of shares of restricted stock to be awarded to non-employee directors as part of their annual and/or new director equity grant, the Board uses the 20-day average closing price of the Company’s common stock for the period preceding the restricted stock grant date. The Board’s fiscal year 2025 non-employee director compensation program is further described below, which reflects an increase in the annual cash compensation and targeted value of the annual restricted stock grant for each non-employee director, as well as an increase in the cash compensation for the Lead Independent Director. • Each non-employee director is entitled to receive cash compensation in the amount of $27,500 per quarter at the time of and upon physical attendance, or attendance via electronic means, at each quarterly Board meeting and is eligible for reimbursement for expenses incurred in attending Board and committee meetings. • Each new non-employee director is entitled to receive a restricted stock grant with a targeted value of $180,000 as of the grant date, which will vest in full on the one-year anniversary of the grant date, so long as the recipient remains a director until such date. • If a new non-employee director does not begin his or her initial term coincident with the occurrence of the Company’s annual meeting of stockholders, then such director shall be entitled to receive his or her applicable Initial Restricted Stock Grant, as described above, on an annualized pro-rata basis covering the time of his or her service up to June 1 immediately following the date of such director’s appointment or election. Each non-employee director continuing his or her service on the Board following the annual meeting of stockholders is entitled to receive a restricted stock grant with a targeted value of $180,000 as of the grant date, which will vest in full on the one-year anniversary of the grant date, so long as the recipient remains a director until such date, provided that if a director does not stand for reelection or is not renominated to stand for election following any such grant of restricted stock, the vesting of any such outstanding restricted stock award shall accelerate and immediately vest as of the date of such recipient’s retirement from the Board. Committee members and chairpersons, as well as the Lead Independent Director, are eligible for additional compensation for their service as follows:

  22. DIRECTOR COMPENSATION

    | Position | Annual Cash Fees(1) ($) | Meeting Fees(2) ($) | Targeted Value of Annual Restricted Stock Grant(3) ($) | Total Value of Annual Compensation ($) | | Audit Committee Chairperson | 20,000 | 1,250 | 20,000 | 40,000 | | Audit Committee Member (non-Chair) | 10,000 | 1,250 | 10,000 | 20,000 | | Compensation Committee Chairperson | 20,000 | 1,250 | 20,000 | 40,000 | | Compensation Committee Member (non-Chair) | 10,000 | 1,250 | 10,000 | 20,000 | | Corporate Governance Committee Chairperson | 11,000 | 1,250 | 11,000 | 22,000 | | Corporate Governance Committee Member (non-Chair) | 7,500 | 1,250 | 7,500 | 15,000 | | Mergers & Acquisitions Committee Member | — | 1,250 | — | — | | Lead Independent Director | 57,500 | — | 17,500 | 75,000 |

  23. DIRECTOR COMPENSATION

    (1) Annual cash fees are paid in four equal installments at each quarterly Board meeting. (2) Represents the per-meeting cash compensation fee received by each member of the M&A Committee for each meeting duly convened and held that such member attends, as well as for certain other non-regularly scheduled meetings of the other committees of the Board duly convened and held that such member attends. Such compensation is paid quarterly in arrears at each quarterly Board meeting. (3) Represents the targeted value of restricted stock granted to each non-employee director serving in such capacity (as a chairperson, committee member or Lead Independent Director, as applicable) as of June 1. Such grant will vest in full on the one-year anniversary of the grant date, so long as the director continues to serve as a director. The table below summarizes, for fiscal year 2025, certain information with respect to the compensation of all non-employee directors of Omnicell. Mr. Lipps, our Chairman, President and CEO, did not receive compensation for serving on the Board. Please see the 2025 Summary Compensation Table for the compensation received by Mr. Lipps for his service as our Chairman, President and CEO.

  24. DIRECTOR COMPENSATION FOR FISCAL YEAR 2025

    DIRECTOR COMPENSATION FOR FISCAL YEAR 2025

  25. DIRECTOR COMPENSATION FOR FISCAL YEAR 2025

    | Director | Fees Earned or Paid in Cash(1) ($) | Stock Awards(2)(3) ($) | Option Awards(4) ($) | All Other Compensation ($) | Total ($) | | Joanne B. Bauer | 140,000 | 215,141 | — | — | 355,141 | | Edward P. Bousa | 106,250 | 196,980 | — | — | 303,230 | | Mary A. Garrett | 115,000 | 215,141 | — | — | 330,141 | | Kaushik “Bobby” Ghoshal | 103,750 | 194,398 | — | — | 298,148 | | Mark W. Parrish | 115,000 | 207,366 | — | — | 322,366 | | Bruce E. Scott | 117,250 | 208,399 | — | — | 325,649 | | Robin G. Seim | 116,250 | 207,366 | — | — | 323,616 | | Eileen J. Voynick | 113,750 | 204,755 | — | — | 318,505 |

  26. DIRECTOR COMPENSATION FOR FISCAL YEAR 2025

    (1) Cash amounts included in this column represent cash fees paid to each non-employee director for his or her Board or committee service during fiscal year 2025. Cash fees are paid on a quarterly basis at each quarterly Board meeting. (2) The dollar amounts in this column represent the grant date fair value of stock awards calculated in accordance with Accounting Standards Codification (“ASC”) Topic 718 “Stock Compensation” (“ASC Topic 718”) based on the closing stock price on the date of grant. (3) The aggregate number of shares subject to restricted stock awards outstanding as of December 31, 2025, all of which were granted in fiscal year 2025, for each of the non-employee directors listed in the table above was as follows: Ms. Bauer, 7,084; Mr. Bousa, 6,486; Ms. Garrett, 7,084; Mr. Ghoshal, 6,401; Mr. Parrish, 6,828; Mr. Scott, 6,862; Mr. Seim, 6,828; and Ms. Voynick, 6,742. No options were granted to the individuals in the table in fiscal year 2025. The aggregate number of shares subject to outstanding stock options held by each of the non-employee directors listed in the table above as of December 31, 2025 was as follows: Ms. Bauer, 0; Mr. Bousa, 0; Ms. Garrett, 0; Mr. Ghoshal, 0; Mr. Parrish, 0; Mr. Scott, 6,381; Mr. Seim, 6,381 and Ms. Voynick, 0.

  27. Executive Changes

    Executive Changes On August 25, 2025, Omnicell appointed Baird Radford its Executive Vice President and Chief Financial Officer. The compensation arrangements for Mr. Radford were driven by individual negotiations pursuant to his employment offer rather than pursuant to the Company’s typical practices. In addition, on November 1, 2025, Mr. Etta, the Company’s former Executive Vice President and Chief Financial Officer, was terminated by the Company without cause. In connection with his termination, Mr. Etta received benefits under the Company’s Executive Severance Plan. Each of these changes impacted executive officer compensation in 2025. Mr. Radford’s compensation arrangements upon his appointment as an executive officer are discussed in the CD&A section titled “Employment Arrangements” below and Mr. Etta’s compensation arrangement upon his termination is discussed in the CD&A section titled “Severance and Change of Control Arrangements.”

  28. Fiscal 2025 Executive Compensation Highlights

    Fiscal 2025 Executive Compensation Highlights The Compensation Committee of our Board (the “Compensation Committee”) took the following key actions with respect to the compensation of our NEOs for fiscal 2025: Base salaries — In March 2025, the Compensation Committee determined to increase the annual base salaries of Messrs. Lipps and Manley by three and one-half percent (3.5%) from fiscal 2024 base salaries. Messrs. Njoku’s and Radford’s 2025 annual base salaries were determined upon their joining the Company based on competitive market data for the respective positions of Executive Vice President and Chief Operating Officer and Executive Vice President and Chief Financial Officer. Performance-based cash bonuses — Our currently-serving NEOs earned annual cash bonuses equal to approximately 133.3% of each such NEO’s total incentive target. • Long-term equity incentive compensation — Each of Messrs. Lipps, Njoku and Manley were granted long-term equity incentive awards in the following forms: • Time-based restricted stock units (“RSUs”), which vest over a four-year period, contingent on continued service; and • Performance-based restricted stock units (“PSUs”), with the potential to earn between 50% and 200% of the target PSU award, provided certain performance criteria are achieved, and which vest 25% immediately on the date that the Compensation Committee formally certifies the Company’s performance and achievement of related performance metrics, with the remaining earned award vesting in equal increments quarterly over the subsequent three-year period, contingent on continued service. In connection with Mr. Radford’s hiring and appointment as Executive Vice President and Chief Financial Officer, he received a one-time sign-on equity award of RSUs with a target grant date value of approximately $1,000,000, which vest over a four-year period, contingent on continued service. Consistent with the Compensation Committee’s prior-year approach to continue to align pay with market factors, reinforce a focus on performance metrics and increase retentive compensation, the long-term equity incentives were delivered approximately 50% in PSUs and 50% in RSUs for Messrs. Lipps, Njoku and Manley. The Compensation Committee believes this mix of equity awards further aligns our executives with the long-term financial interests of our stockholders, while providing an appropriate level of retentive and performance-based compensation. In light of Mr. Etta’s separation, the Compensation Committee did not grant 2025 long-term incentive awards to Mr. Etta. As noted, Mr. Radford received a one-time sign-on equity award of RSUs in connection with his hiring and appointment as Executive Vice President and Chief Financial Officer of the Company. • Randall A. Lipps Employment Agreement. As previously disclosed, in March 2025, Omnicell entered into an employment agreement with Mr. Lipps pursuant to which he will continue to serve as the Company’s President and Chief Executive Officer (the “CEO Employment Agreement”). The CEO Employment Agreement has a term through December 31, 2027 and provides the payments and benefits to which Mr. Lipps is entitled including:(i) an annual base salary, (ii) eligibility for a participation in the annual cash bonus program, and (iii) an annual long-term incentive award, as well as continued eligibility for benefits the Company may provide from time to time to similarly situated employees and to participate in the benefit plans and allowances for which he is currently eligible to the extent the Company continues to provide such benefits to employees in general. In addition, Mr. Lipps will also be eligible for certain severance and change of control benefits under the CEO Employment Agreement. Mr. Lipps’ compensation arrangements are further discussed in the CD&A section titled “Employment Arrangements” below.

  29. Elements of Our Executive Compensation Program

    | Compensation Element | | Type | Primary Objective(s) | Performance Measures | | Annual Base Salary | | Fixed | Provide base amount of market competitive pay and predictable level of financial stability | Not applicable, although adjustments may be made to recognize individual performance | | Annual Cash Performance- Based Bonus | | At-risk | Incentivize and reward the achievement (and over- achievement) of short-term corporate and individual goals | Corporate Threshold Targets: • Non-GAAP EBITDA (annual) • Total Revenue (annual) • Total Annual Recurring Revenues (annual) • Executive Goals (annual) | | Long-Term Equity Incentive Awards | PSUs | At-risk | Incentivize and retain executives, align the interests of stockholders and executives, and motivate and reward achievement of long-term corporate financial goals (no payout if performance measure is not met) | Total stockholder return over a one-year performance period as measured against certain companies in the healthcare sector of the S&P 400 and S&P 600 indexes (the “S&P 1000 Healthcare Index”) | | | RSUs | Variable | Incentivize and retain executives and align the interests of stockholders and executives by linking realized value to stock price performance | Value is dependent upon stock price |

  30. Role of Compensation Consultant

    Role of Compensation Consultant The Compensation Committee engaged the services of Exequity in 2025, to serve as an independent advisor to the Compensation Committee to assist in reviewing the compensation of the Company’s executive officers. At the request of the Compensation Committee, Exequity identified companies for a competitive market analysis, as discussed in the section below entitled “Competitive Market Analysis.” Exequity ultimately developed recommendations regarding 2025 executive compensation levels and types of compensation elements that were presented to the Compensation Committee for its consideration. For additional information regarding the engagement of Exequity as compensation consultant and its roles in advising with respect to our 2025 executive compensation, please refer to the section above entitled “Board and Corporate Governance Matters — Information Regarding Compensation Committees of the Board of Directors — Compensation Committee — Compensation Committee Processes and Procedures.”

  31. Competitive Market Analysis

    Competitive Market Analysis As part of its engagement, Exequity worked closely with the Compensation Committee to identify comparable peer companies, provided the Compensation Committee with reports summarizing a comparison of the total compensation of our executive officers with such peer companies and provided an assessment of the specific elements of our executive compensation components in relation to the peer companies. The Compensation Committee believes a competitive market analysis of executive compensation is crucial to maintaining compensation levels competitive with other leading technology companies with which we compete for personnel. Additionally, the competitive market analysis provides guideposts, that the Compensation Committee uses to determine the size, mix and components of executive compensation. Historically it has been, and continues to be, challenging to find appropriately sized industry competitors for comparison. Therefore, the Compensation Committee, with the assistance of Exequity, has developed a group of publicly traded companies viewed as comparable to the Company based on the following selection criteria that we believe provides a meaningful cross section from which to benchmark executive compensation: Companies with similar revenue size to ours (i.e., approximately 0.5 times to 3.0 times our then-current trailing twelve-month revenue); • Companies with a similar market capitalization, enterprise value, EBITDA, or number of employees as ours; • Companies with similar financial structures or limitations (i.e., cyclicality, outsourcing strategies); • Industry similarity, to the extent possible, with a primary focus on three industry subcategories that we believe are representative of portions of our business: the healthcare management and software industry; the medical equipment and supplies industry; and the logistics and supply chain management and manufacturing industry (software companies are also considered and included where appropriate); and • Companies, to the extent reasonable, with which we believe we may compete for executive personnel. For the decisions relating to the 2025 compensation of our NEOs (other than Mr. Radford), including the long-term equity compensation awards approved for Messrs. Lipps, Njoku and Manley in March 2025, the Compensation Committee utilized a report prepared by Exequity in late 2024 (the “2025 Peer Group Report”). To the extent that there are statements relating to percentiles included in this CD&A, they are intended to reference performance against peer companies as identified in the 2025 Peer Group Report. Mr. Radford joined the Company and was appointed Executive Vice President and Chief Financial Officer in August 2025 and his compensation levels were determined in connection with his hiring. In connection with Mr. Radford’s employment offer, the Compensation Committee considered market data gathered by Exequity based on companies in our 2025 peer group as identified in the 2025 Peer Group Report, as well as other factors discussed below in the section entitled “Elements of Compensation and 2025 Determinations.” The companies identified for benchmark comparison in the 2025 Peer Group Report and selected by the Compensation Committee as our 2025 peer group were as follows:

  32. Competitive Market Analysis

    | 2025 Peer Group | | | | • ACI Worldwide, Inc. | • Haemonetics Corporation | • Masimo Corp. | | • Avanos Medical, Inc. | • HealthEquity, Inc. | • MultiPlan, Inc. | | • Blackbaud Inc | • ICU Medical, Inc. | • Nutanix, Inc. | | • CONMED Corporation | • Inspire Medical Systems, Inc. | • Orthofix Medical Inc. | | • Evolent Health, Inc. | • Integer Holdings Corporation | • Pegasystems Inc. | | • Globus Medical, Inc | • Integra LifeSciences Holdings Corporation | • Tandem Diabetes Care, Inc. | | • GoodRx Holdings, Inc. | • LivaNova PLC | • Varex Imaging Corporation |

  33. Competitive Market Analysis

    The Compensation Committee and its compensation consultant strive to maintain a consistent peer group year over year for comparability of competitive analysis. However, on a yearly basis, the peer group is reviewed and refined to take into consideration comparability of peer companies’ financial performance relative to Omnicell, as well as the acquisition of or any fundamental changes in the peer companies’ operating businesses. As part of this review process, the Compensation Committee made the following changes to the 2024 peer group in determining the 2025 peer group: • Removed Agiliti, Inc. as it was acquired in May 2024 and R1 RCM Inc., as its acquisition was announced in February 2024; • Removed ModivCare Inc., Teladoc Health, Inc. and Veradigm Inc., as they no longer matched the peer group selection criteria described above; and • Added the following companies due to: (i) being a competitor in the software-as-a service space, and/or (ii) financial profile or size comparability: Avanos Medical, Inc., Inspire Medical Systems, Inc. LivaNova PLC, Orthofix Medical Inc., Premier, Inc., Tandem Diabetes Care, Inc. and Varex Imaging Corporation. As of the date of the 2025 Peer Group Report, our revenue registered at the 37th percentile of the companies in the 2025 peer group and our market capitalization registered at the 17th percentile of the companies in the 2025 peer group.

  34. Cash Compensation

    Cash Compensation Overview. The cash component of our executive compensation program serves a two-fold purpose. Base salaries are intended to provide financial stability, predictability and security of compensation for our executive officers for fulfilling their core job responsibilities, while the performance-based cash bonus plan is intended to incentivize and reward the achievement of predetermined corporate and individual short-term objectives. The Compensation Committee’s objective that provides guidance in its cash compensation decision-making has been to provide each executive officer with (i) a target total cash compensation opportunity at or near the 50th percentile for comparable positions identified in the 2025 Peer Group Report, with the potential for actual higher or lower total cash compensation to be earned dependent upon the achievement of underlying performance objectives, and (ii) base salary at approximately the 50th percentile for comparable positions identified in the 2025 Peer Group Report. The Compensation Committee analyzes compensation from the 2025 Peer Group Report, input from Exequity, and management’s financial forecasts for the upcoming fiscal year to determine the level of each component of an executive’s total cash compensation targets. The Compensation Committee takes into consideration a competitive market analysis of competitive pay practices for comparable positions identified in the 2025 Peer Group Report, with a view toward maintaining consistent bonus percentages among the Company’s executive officers and targeting total cash compensation at or near the 50th percentile for each executive officer as compared to the peer group. The Compensation Committee determined the base salary for Mr. Radford, who joined the Company in August 2025, taking into consideration various factors including market data gathered by Exequity for comparable positions based on our 2025 peer group, the scope of Mr. Radford’s role, his qualifications and prior experience, other input provided by Exequity and the recommendation of our CEO. 2025 Base Salary and Total Cash Compensation Determination. In determining targeted total cash compensation for 2025, the Compensation Committee used its objective of targeting base salary and total cash compensation at or near the 50th percentile as guidance, including performance-based cash compensation elements, in each case as compared to the peer group The table below sets forth, for each NEO other than Mr. Radford, 2025 base salary and the targeted total cash compensation approved by the Compensation Committee in March 2025, and the percentage increase such approved 2025 targeted total cash compensation represented from the 2024 targeted total cash compensation that was approved.

  35. Cash Compensation

    2025 base salary and 2025 targeted total cash compensation refer to an executive officer’s annualized salary and incentive target effective July 2025, assuming, in the case of 2025 targeted total cash compensation, achievement of 100% of the Company’s Executive Goals (as defined below) and the achievement of the 2025 performance metrics (as described below). (2) 2024 base salary and 2024 targeted total cash compensation refer to an executive officer’s annualized salary and incentive target effective July 2024, assuming, in the case of 2024 targeted total cash compensation, achievement of 100% of the Company’s Executive Goals (as defined below) and achievement of the 2024 performance metrics (as described below). (3) Due to the timing of Mr. Njoku’s appointment as Executive Vice President and Chief Operating Officer, he was only eligible in 2024 for a special fourth quarter cash bonus with a target value of $161,250, subject to achieving certain onboarding and assimilation goals, in connection with Mr. Njoku’s hiring which amount is currently reflected in his “2024 Targeted Total Cash Compensation”. If Mr. Njoku would have been eligible for participation in the Company’s annual executive bonus plan, his total targeted cash compensation for 2024 would have been $1,290,000. Performance-Based Bonus. The second component of cash compensation for our executive officers is a performance-based bonus, which is intended to be a substantial component of our executives’ cash compensation. The Compensation Committee determines each executive officer’s performance-based bonus target (as a percentage of his or her base salary), taking into consideration the competitive market analysis in the 2025 Peer Group Report, with a view towards maintaining consistent bonus percentages amongst the Company’s executive officers and targeting total cash compensation at or near the 50th percentiles for each executive officer as compared to the 2025 peer group. The performance-based bonus target percentages for 2025 (excluding Mr. Njoku) remained the same as those determined by the Compensation Committee for 2024. Due to the timing of Mr. Njoku’s appointment as Executive Vice President and Chief Operating Officer, in 2024 he was only eligible for a special fourth quarter cash bonus with a target value of $161,250, subject to achieving certain onboarding and assimilation goals, in connection with Mr. Njoku’s hiring which amount is currently reflected in his “2024 Targeted Total Cash Compensation”. If Mr. Njoku had been eligible for participation in the Company’s annual executive bonus plan, his performance-based bonus target percentage would have been 100% of his base salary. In 2024, the Compensation Committee adopted the Omnicell, Inc. Executive Bonus Plan (“Bonus Plan”). The Compensation Committee determined to utilize the Bonus Plan to determine the performance-based bonuses for the Company’s executive officers for 2025. The Bonus Plan provides our executive officers with the potential to earn between 0% – 200% of his or her target bonus payout upon meeting certain annual performance metrics, which may be weighted between 0% – 100%. Under the Bonus Plan, the Company established annual threshold, target, and maximum performance metrics. Achievement of the threshold, target and maximum performance metrics results in a payment of 50%, 100%, and 200%, respectively, of the target bonus. There are linear changes between threshold, target, and maximum payouts. The bonus is further subject to modification dependent upon the Company’s achievement of the annual executive goals (“Executive Goals”). Failure to meet an Executive Goal results in forfeiture of the percentage of cash bonus associated with the Executive Goal, subject to a maximum forfeiture amount of up to 20% of an executive officer’s 2025 bonus payout. For example, if the Company had three Executive Goals that were equally weighted (i.e., each Executive Goal was worth 33%), if the Company failed to meet one Executive Goal but met the other two Executive Goals, the executive would be eligible to receive only 93% of the annual bonus payout. So, if the Company would have achieved a maximum bonus payout (i.e., 200% of targeted bonus payout), an executive would be entitled to receive a bonus payout of 186% (93% x 200%)). 2025 Performance Metrics. For 2025, the performance metrics for our executive officers’ bonuses were non-GAAP EBITDA (40%), total revenue (40%) and total annual recurring revenue (20%). The Compensation Committee selected these performance metrics to further emphasize a focus on profitable growth. The Compensation Committee established annual performance goals for each of these three performance metrics.

  36. 2025 Performance Metric Targets and Bonus Determination

    2025 Performance Metric Targets and Bonus Determination The Compensation Committee established the 2025 performance metric targets at the beginning of 2025, and such targets were intended to incent the executive officers to achieve results that were consistent with the Company’s board-approved financial plan. The actual amount of each target was set by the Compensation Committee based on a combination of the input of management, historical annual results, the Company’s desired growth, financial forecasts and analyst expectations, as well as the Company’s views on the market environment and expected headwinds and macroeconomic uncertainty for 2025. The following table sets forth the performance metrics applicable to the NEOs and actual performance for 2025:

  37. 2025 Performance Metric Targets and Bonus Determination

    | Non-GAAP EBITDA(1) (40%) | | | | Total Revenues (40%) | | | | Total Annual Recurring Revenue(2) (20%) | | | | | Threshold (50%) | Target (100%) | Max (200%) | Actual | Threshold (50%) | Target (100%) | Max (200%) | Actual | Threshold (50%) | Target (100%) | Max (200%) | Actual | | (amounts in millions) | | | | | | | | | | | | | $137.0 | $157.0 | $177.0 | $139.9 | $1,123.0 | $1,153.0 | $1,183.0 | $1,184.8 | $613.0 | $628.0 | $643.0 | $635.6 |

  38. 2025 Performance Metric Targets and Bonus Determination

    (1) Non-GAAP EBITDA for incentive purposes represents the Company’s as-reported non-GAAP EBITDA for fiscal year 2025 and is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation expenses pursuant to ASC Topic 718, as well as excluding certain other non-GAAP adjustments such as acquisition-related expenses, amortization of debt issuance costs, EnlivenHealth restructuring, RDS restructuring, legal and regulatory expenses, management severance costs, and executive transition costs. (2) Total Annual Recurring Revenue (“ARR”) for incentive purposes represents the Company’s as-reported Total Annual Recurring Revenue for fiscal year 2025. We consider revenues generated from our consumables, technical services, and SaaS and Expert Services to be recurring revenues. We define ARR at a measurement date as the revenue we expect to receive from our customers over the course of the following year for providing them with products or services. ARR includes expected revenue from all customers who are using our products or services at the reported date. For technical services and SaaS and Expert Services, solutions are generally on a contractual basis, typically with contracts for a period of 12 months or more, with a high probability of renewal. Probability of renewal is based on historic renewal experience of the individual revenue streams or management’s best estimates if historical renewal experience is not available. Consumables orders are placed by customers through our Omnicell Storefront online platform or through written or telephonic orders and are sold to a customer base who utilize the consumable product and place recurring orders when customer inventory is depleted. ARR is generally calculated based on revenues received in the most recent quarter and changes to expected revenues where solutions were added to or removed from the install or customer base in the quarter. Revenues from technical services and SaaS and Expert Services are generally recorded ratably over the service term. Revenue from consumables are recorded when the product has shipped and title has passed. Our measure of ARR may be different than that used by other companies. Because ARR is based on expected future revenue, it does not represent revenue recognized during a particular reporting period or revenue to be recognized in future reporting periods. ARR should not be viewed as a substitute for GAAP revenues. For fiscal year 2025, the Compensation Committee determined that the Company achieved a performance of 89.1% of target for non-GAAP EBITDA, 102.8% of target for total revenue and 101.2% of target for total annual recurring revenue, resulting in payout funding of approximately 133.3% of the target bonus for each of Messrs. Lipps, Njoku, Radford, Etta, and Manley. The Company’s annual as reported non-GAAP EBITDA, total revenue and total annual recurring revenue for 2025 were the basis for measuring the level of non-GAAP EBITDA, total revenue and total annual recurring revenue to determine the achievement of the performance targets. The Compensation Committee believes that the structure of the Bonus Plan emphasizes its desire to motivate individual performance, while retaining the Company’s financial performance as paramount and the primary focus of each executive’s efforts. Executive Goals. For 2025, the Compensation Committee established Executive Goals for the executive officers and determined achievement of such targets. The Executive Goals are designed to encourage progress in, and create a strong incentive for, the executives to excel in areas that are primarily within their control, while emphasizing the importance of the Company’s success by requiring achievement of the Corporate performance metrics before bonus eligibility. In 2025, the Compensation Committee approved three Executive Goals for our NEOs, which focused on objectives in the following areas: (1) Operating Objectives related to talent retention and recruitment, (2) Strategic Objectives related to customer health, satisfaction, and strengthening market position, and (3) Transformational Objectives that involve reimagining the customer experience. Each Executive Goal is given a percentage weighting such that achievement of all Executive Goals corresponds to 100% funding of the annual bonus payout. Each of the Operational and Strategic Objectives was weighted at 25% of an executive officer’s annual bonus payout and the Transformational Objective was weighted at 50% of an executive officer’s annual bonus payout. Total Cash Bonuses Earned. The following table sets forth, for each participating NEO, the Incentive Target, total earned incentive bonuses, and the percentage of total Incentive Target earned for 2025:

  39. 2025 Performance Metric Targets and Bonus Determination

    | Named Executive Officer | 2025 Incentive Target(1) ($) | Total 2025 Cash Bonus Earned ($) | % of Total 2025 Incentive Target Earned (%) | | Randall A. Lipps | 1,058,614 | 1,411,485 | 133.3 | | Baird Radford | 143,567(2) | 191,423 | 133.3 | | Nnamdi T. Njoku | 645,000 | 860,000 | 133.3 | | Corey J. Manley | 374,961 | 499,948 | 133.3 | | Nchacha E. Etta | 404,481 | 539,308 | 133.3 |

  40. 2025 Performance Metric Targets and Bonus Determination

    (1) The amounts contained in this table differ from the amounts as set forth in “Grants of Plan-Based Awards in Fiscal 2025” below due to portions of the 2025 Incentive Target for each NEO being based on portions of the NEO’s annual base salary for 2024. (2) The 2025 Incentive Target for Mr. Radford reflects the cash bonus for which Mr. Radford was eligible based on the date he joined Omnicell.

  41. Equity Compensation

    Equity Compensation Overview. Long-term equity-based compensation is intended to incentivize and retain our executive officers through the tying of our long-term financial performance to the executive officer’s financial success using a mix of time-based vesting and performance-based vesting. We believe that the combination of both time-based vesting and performance-based vesting, with shared financial success are long-term incentives that motivate our executive officers to grow revenues and earnings, enhance stockholder value and align the interests of our stockholders and executives over the long-term. Equity-based compensation is awarded in two components: (i) RSUs that vest over time if the executive remains employed with the Company and (ii) PSUs that initially vest only upon the achievement of the Company TSR index performance metric described below, and provided the performance metric is achieved, thereafter vest over time if the executive remains employed with the Company. Generally, on an annual basis, the Compensation Committee makes an assessment as to the size and type of additional equity awards, if any, to be given to each executive officer. PSUs are intended to provide the most substantial incentive to our executive officers to improve Company performance and to positively affect stock value, while RSUs provide an element of long-term incentive that has greater retention value in a flat or down market but with the value of the award still fluctuating based on our stock price performance. Annual awards granted in 2025 vest over four years as follows: (i) in the case of service-based RSUs, 25% on the one year anniversary of the grant and the remaining 75% vesting in equal increments quarterly on February 15, May 15, August 15 or November 15, over the subsequent three year period and (ii) in the case of PSUs, 25% immediately on the date that the Compensation Committee formally certifies the Company’s performance and achievement of related performance metrics, with the remaining earned award vesting in equal increments quarterly on February 15, May 15, August 15 or November 15, over the subsequent three-year period. The size of the initial grant and the annual grants are determined by the Compensation Committee based upon factors including: competitive equity compensation practices for comparable positions identified in the 2025 Peer Group Report; the executive’s level of responsibility and duties; • comparison to grant levels of other executive officers; • individual executive officer performance; • corporate performance; • the executive’s prior experience, experience within his or her specific job and breadth of knowledge; and • corporate objectives for share-based compensation charges and earnings dilution. On an annual basis, management and the Compensation Committee establish a maximum aggregate share-based compensation expense for the executive awards, taking into consideration anticipated share-based compensation expenses for equity grants to other employees. The Compensation Committee balances this percentile objective with its commitment to stay within management’s share-based expense objective in finalizing the aggregate and individual awards. In determining equity compensation for the executive officers, the Compensation Committee reviews the equity compensation grants over a three-year period against a three-year rolling benchmark identified in the 2025 Peer Group Report with an objective of making awards at or near the 50th percentile (on a value basis) over the three-year period. In addition to the factors discussed above, with respect to the size of the awards on a year-over-year basis, the Compensation Committee also takes into consideration the following factors when determining the size and mix of the equity grants: • the combined size of the awards over a three-year period; • the effect of the awards on dilution; • our total equity compensation costs relative to total expenses; and • competitive equity compensation practices for comparable positions identified in the 2025 Peer Group Report. With respect to Mr. Radford, upon commencement of his employment and appointment, he was awarded an initial time-based equity grant of RSUs carrying a service-based vesting condition, with 25% of the shares subject to the grant vesting on February 15, May 15, August 15 or November 15, whichever date is closest immediately following the one year anniversary of the grant, and the remaining 75% of the shares subject to vesting quarterly in equal increments over the following three years. 2025 Equity Awards. In March 2025, the Compensation Committee approved executive equity grants with approximately 50% of the grants subject to performance-based vesting and 50% subject to time-based vesting for our NEOs (excluding the one-time sign on equity award of RSUs granted to Mr. Radford in connection with his hiring and appointment as Executive Vice President and Chief Financial Officer of the Company given the one-time nature of this award and that the award is not representative of the Company’s typical compensation practices), to further align pay with market factors, reinforce a focus on performance metrics and increase retentive compensation. As in past years when setting the level of grants, the Compensation Committee took into consideration, to the extent applicable, corporate performance and individual contributions in 2024. The Compensation Committee also reviewed, assessed and took into consideration competitive equity compensation practices for comparable positions identified in the 2025 Peer Group Report. This input, and the Compensation Committee’s desire to maintain equity compensation expense within management’s established objective, resulted in the Compensation Committee setting a target percentile for our total equity awards at or near the 50th percentile as compared to the peer group in the Exequity Report, including performance-based equity compensation elements. With respect to our continuing NEOs (excluding Mr. Radford), the Compensation Committee set ratios for 2025 equity awards of 50% PSUs and 50% RSUs. The ratio of time-based and performance-based vesting was set based on the targeted award size, the retention and incentive aspects of each type of award as well as an analysis of competitive market trends amongst our 2025 peer group. In granting the various equity awards to our NEOs, the Compensation Committee used the average closing price of our common stock as quoted on the Nasdaq Global Select Market for 20 trading days immediately prior to the grant date ($40.10) to determine the number of shares subject to each award and the ratio among the various awards. For example, based on the framework described above, if the Compensation Committee were to recommend granting $1,000,000 in target grant equity value to an NEO, the executive would be granted approximately 12,469 RSUs (or $1,000,000 times 50% divided by $40.10) and approximately 12,469 PSUs (or $1,000,000 times 50% divided by $40.10). This is reflected in the table below setting forth our 2025 equity awards.

  42. Equity Compensation

    As the Compensation Committee used the average closing price of our common stock as quoted on the Nasdaq Global Select Market for 20 trading days immediately prior to the grant date ($40.10) to determine the number of shares subject to each award, based on the application of ASC Topic 718, the amounts reported for our NEOs in the 2025 Summary Compensation Table below deviate from the targeted value approved by the Compensation Committee. The 2025 Summary Compensation Table below reflects the grant date fair values of the various awards granted to each NEO calculated in accordance with ASC Topic 718 as follows: (i) the closing price of our common stock on March 14, 2025 was $33.00 (for Mr. Radford the closing price of our common stock on November 14, 2025 was $35.12), the value used to determine the grant date fair value of each RSU, and (ii) the value for each PSU using Monte Carlo methodology was $32.66. The following table sets forth the equity awards granted by the Compensation Committee under the 2009 Equity Incentive Plan to our participating NEOs in February 2025:

  43. Equity Compensation

    | Named Executive Officer | Number of RSUs(1) | Number of PSUs(2) | | Randall A. Lipps | 79,494 | 79,494 | | Nnamdi T. Njoku | 37,409 | 37,409 | | Corey J. Manley | 22,445 | 22,445 |

  44. Equity Compensation

    (1) RSUs were granted pursuant to the 2009 Equity Incentive Plan. The right to receive the shares underlying the RSU grant vest as to 25% of the shares subject to the grant on March 1, 2026, with the remaining 75% of shares subject to each grant vesting in 12 equal quarterly increments on each of February 15, May 15, August 15 and November 15 over the three following years. Vesting is contingent upon continued service. (2) PSUs were granted pursuant to the 2009 Equity Incentive Plan. The right to receive the shares underlying the PSU grant vest according to the description set forth in “Performance-Based Restricted Stock Unit Awards” below. The Company’s total stockholder return was approximately at the 60th percentile of the S&P 1000 Healthcare Index for 2025; however, as the Company’s total stockholder return for 2025 was less than zero, the percentage of the target number of PSUs eligible to be earned was capped at 100%. As a result, 100% of the target number of shares subject to the awards granted are eligible for vesting. Based on this, our NEOs earned the following amounts of PSUs: Mr. Lipps: 79,494 Mr. Njoku: 37,409; and Mr. Manley: 22,445. Vesting is contingent upon continued service. As previously noted, in connection with Mr. Etta’s departure, he was not granted long-term incentive compensation in fiscal 2025. In connection with joining the Company, Mr. Radford was awarded a sign-on grant of RSUs with a target grant date value of approximately $1,000,000 (32,932 RSUs). Consistent with how the Board has historically approached new executive officer appointments, Mr. Radford was provided a sign-on grant to: (1) further align new executive and shareholder interests, (2) to make the new executive whole for compensation that may have been forfeited from their previous employer, and (3) to induce the candidate to accept employment with the Company. The right to receive the shares underlying the grant of RSUs vests as to 25% of the shares subject to the grant on November 15, 2026, with the remaining 75% of the shares subject to the grant vesting in equal quarterly increments on February 15, May 15, August 15 and November 15 over the three following years. Vesting is contingent upon continued service. Performance-Based Restricted Stock Unit Awards. The number of 2025 PSUs earned that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the S&P 1000 Healthcare Index. Stock price appreciation is calculated based on the trailing 20-day average stock price just prior to the first trading day of March in the grant year, compared to the trailing 20-day average stock price just prior to the first trading day of March in the year subsequent to the grant year. The following table shows the percent of PSU awards eligible for further time-based vesting based on our percentile placement:

  45. Equity Compensation

    | Percentile Placement of Our Total Stockholder Return | Percentage of Target PSUs Awarded | | Below the 35th percentile | 0% | | At or above the 35th percentile, but below the 50th percentile | 50 – 99% (interpolated) | | At or above the 50th percentile, but below the 90th percentile | 100 – 199% (interpolated) | | At or above the 90th percentile | 200% |

  46. Equity Compensation

    On March 5, 2026, the Compensation Committee calculated that the Company’s total stockholder return based on the calculations above was at approximately the 60th percentile of the S&P 1000 Healthcare Index for 2025; however, as the Company’s total stockholder return for 2025 was less than zero, the percentage of the target number of PSUs eligible to be earned was capped at 100%. Therefore, approximately 100% of the target number of shares subject to the PSUs granted in March 2025 are eligible for vesting. The earned PSUs will vest as follows: 25% of the shares vested on March 15, 2026 the one year anniversary of the grant date, with the remaining shares vesting twelve equal quarterly increments on May 15, August 15, November 15, and February 15. Vesting is contingent upon continued service. Employment Arrangements. Each of our executive officers is an “at-will employee.” We have entered into written employment agreements with each of our NEOs. The primary elements covered in these employment agreements include: initial base salary, equity awards, eligibility to participate in the executive bonus plan, and inclusion in the Executive Severance Plan, which provides for certain severance benefits as further described under the section titled “Severance and Change of Control Arrangements.” With respect to Mr. Lipps, as further described in “Randall A. Lipps Employment Agreement” below, his employment agreement covers the following elements: base salary, equity awards and eligibility to participate in the executive bonus plan, as well as certain severance benefits under specified scenarios. Baird Radford Compensation. Mr. Radford joined Omnicell in August 2025 as Executive Vice President and Chief Financial Officer. Taking into account various factors, including market data gathered by Exequity for comparable positions based on our 2025 peer group, the scope of Mr. Radford’s role, his qualifications and prior experience, other input provided by Exequity and the recommendation of our CEO, the Compensation Committee determined the annual base salary, performance-based bonus target and long-term equity incentive compensation for Mr. Radford. The primary elements covered in Mr. Radford’s employment agreement consist of: (i) a base salary of $525,000; (ii) a one-time equity award with a targeted grant date value of approximately $1,000,000 in the form of RSUs with the vesting described above; (iii) participation in the Bonus Plan with a target cash bonus of 90% of his annual base salary; and (iv) inclusion in the Executive Severance Plan, as described under the section titled “Severance and Change of Control Arrangements”. Randall A. Lipps Employment Agreement. In March 2025, Omnicell entered into an employment agreement with Mr. Lipps pursuant to which he will continue to serve as the Company’s President and Chief Executive Officer (the “CEO Employment Agreement”). The CEO Employment Agreement has a term through December 31, 2027. During the term of the CEO Employment Agreement, the payments and benefits to which Mr. Lipps is entitled include:(i) an annual base salary of no less than $833,000, (ii) eligibility for an annual cash bonus targeted at not less than 125% of his then-current base salary, and (iii) an annual long-term incentive award having a target grant date fair value of no less than $6,375,000. Mr. Lipps will also continue to be eligible for benefits the Company may provide from time to time to similarly situated employees and to participate in the benefit plans and allowances for which he is currently eligible to the extent the Company continues to provide such benefits to employees in general. In addition, Mr. Lipps will also receive certain severance and change of control benefits under the CEO employment agreement as further described in “Severance and Change of Control Arrangements — CEO Employment Agreement” below. Nchacha E. Etta Separation Agreement. In connection with his termination by the Company without cause, Mr. Etta received benefits under the terms of the Executive Severance Plan. In addition, the Compensation Committee approved: (i) Mr. Etta’s continued participation in the Bonus Plan (excluding the requirement that Mr. Etta be employed by the Company on the last day of the performance year), and (ii) an additional year of vesting credit for Mr. Etta’s outstanding equity awards, as further described in “Severance and Change of Control Arrangements — Equity Award Acceleration” below. Other Benefits and Compensation Practices. Director and Executive Officer Stock Ownership Guidelines. Pursuant to our stock ownership guidelines, each Board member and executive officer are expected to beneficially own not less than the following amount of our common stock (as a multiple of their respective compensation):

  47. Equity Compensation

    | Board Members | 5x annual cash retainer | | Chief Executive Officer | 6x annual base salary | | Other Executive Officers | 3x annual base salary |

  48. Equity Compensation

    Individuals have five years from becoming subject to these guidelines to attain the ownership levels. If an individual becomes subject to a greater ownership amount, due to a promotion or an increase in base salary or due to revisions to these guidelines, the individual is expected to meet such higher ownership amount within the later of the original period or three years from the effective date of the promotion, base salary change or revision. As of May 2025, each of our then-serving NEOs satisfied our stock ownership guidelines or was in the five-year phase-in period. Severance and Change of Control Benefits. The Omnicell, Inc. Executive Severance Plan (the “Executive Severance Plan”) provides severance benefits to certain key management personnel of the Company and its subsidiaries, including those with the title of Executive Vice President or higher whose employment is terminated (i) by the Company for any reason other than for cause, death or disability; or (ii) during the 24-month period following the occurrence of a change in control (as defined in the Executive Severance Plan) of the Company by the covered executive for good reason. Each of the NEOs were designated as participants in the Executive Severance Plan. The terms of the Executive Severance Plan are described in more detail below in the sections entitled “Severance and Change of Control Arrangements” and “Potential Payments Upon Termination or Change of Control.” Other Benefits. We believe that establishing a competitive benefit package consistent with companies with which we compete for employees is an important factor in attracting and retaining talented employees. Thus, we provide our executive officers with employee benefits on the same basis as offered to our full time non-executive employees, including health and dental insurance, supplemental life insurance, short- and long-term disability and a 401(k) plan. Incentive Compensation Recoupment Policy. We maintain a Policy on Recoupment of Incentive Compensation, which governs the recovery of erroneously awarded incentive-based compensation. Our policy is consistent with the requirements of the Securities and Exchange Commission and the Nasdaq Stock Market and provides that, if we are required to prepare an accounting restatement, then unless an exception applies, we will recover as promptly as reasonably possible, any erroneously awarded incentive-based compensation. Perquisites. The Compensation Committee believes that perquisites and other personal benefits should be modest and reasonable and consistent with our desire to enhance the executive’s work effectiveness and to otherwise facilitate a balance of his or her personal and work requirement trade-offs. The Compensation Committee periodically reviews the levels of perquisites and other personal benefits provided to the executive officers and, from time to time, may modify the perquisites and personal benefits provided to better align with market practice. We provide each executive officer with an annual perquisite allowance ($40,000 for Mr. Lipps and $16,000 for each other executive officer) for comprehensive financial counseling and tax planning services, as well as an additional reimbursement of up to $6,000 every three years for legal advice related to estate planning, and reimbursement of up to $6,000 annually for a comprehensive annual physical. We believe that these perquisites allow us to maintain the competitiveness of our compensation package and allow our executive officers to better focus on running the business. By not adding these perquisites to salary, we do not increase our bonus payouts, cost of severance or other elements of pay.

  49. Summary Compensation Table

    Summary Compensation Table The following table shows compensation awarded to, paid to or earned by the NEOs for the fiscal years ended December 31, 2025 and, to the extent required by SEC disclosure rules, 2024 and 2023:

  50. 2025 SUMMARY COMPENSATION TABLE

    2025 SUMMARY COMPENSATION TABLE

  51. 2025 SUMMARY COMPENSATION TABLE

    | Named Executive Officer | Year | Salary ($) | Bonus ($) | Stock Awards ($)(1) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($)(2) | All Other Compensation ($) | Total ($) | | Randall A. Lipps Chairman, President and Chief Executive Officer | 2025 | 846,891 | — | 5,219,576 | — | 1,411,485 | 53,900(3) | 7,531,852 | | | 2024 | 822,482 | — | 6,009,274 | — | 1,289,241 | 53,642 | 8,174,639 | | | 2023 | 813,100 | — | 9,174,870 | — | 985,102 | 49,000 | 11,022,072 | | H. Baird Radford, III Executive Vice President, Chief Financial Officer(4) | 2025 | 159,519 | — | 1,156,572(5) | | 191,423 | 6,000(6) | 1,513,514 | | Nnamdi T. Njoku Executive Vice President, Chief Operating Officer | 2025 | 645,000 | — | 2,456,275 | | 860,000 | 43,839(7) | 4,005,114 | | | 2024 | 124,038 | — | 2,444,258 | — | 161,250 | 7,613 | 2,737,159 | | Corey J. Manley Executive Vice President, Chief Legal and Administrative Officer | 2025 | 416,623 | | 1,473,739 | — | 499,948 | 65,700(8) | 2,456,010 | | | 2024 | 404,615 | 26,551 | 1,790,999 | — | 456,649 | 36,404 | 2,715,218 | | | 2023 | 386,923 | — | 2,342,520 | — | 306,761 | 21,642 | 3,057,846 | | Nchacha E. Etta Former Executive Vice President, Chief Financial Officer | 2025 | 449,423 | — | — | | 539,308 | 996,427(9) | 1,985,158 | | | 2024 | 480,481 | — | 2,120,904 | — | 515,720 | 21,733 | 3,138,838 | | | 2023 | 259,423 | 50,000 | 4,678,230 | — | 161,792 | 9,000 | 5,158,445 |

  52. 2025 SUMMARY COMPENSATION TABLE

    (1) The dollar amounts represent the grant date fair values of restricted stock units calculated in accordance with ASC Topic 718 using (i) the product of the number of shares granted and the closing market price of our common stock on the grant date for time-based RSUs, and (ii) for PSUs, a Monte Carlo simulation model applying a multiple awards approach. Under ASC Topic 718, the vesting condition related to the PSUs is considered a market condition and not a performance condition. Accordingly, there is no other grant date fair value other than as reflected in the table above for the NEOs that could be calculated and disclosed based on achievement of the underlying market condition. (2) The amounts set forth in this column for 2025 reflect the compensation earned by the NEOs for the year ended December 31, 2025 under the Bonus Plan. (3) Consists of a $40,000 annual perquisite allowance for financial comprehensive financial counseling and tax planning services paid to Mr. Lipps, an allowance for legal advice related to estate planning, an allowance for a comprehensive annual physical as described above, an employer 401(k) match, and certain incremental costs incurred in connection with our executive officer and their spouse’s or guest’s attendance at certain of the Company’s business events related to air travel, meals, activities and any other incidental event-related expenses. (4) Mr. Radford joined Omnicell and was appointed Executive Vice President and Chief Financial Officer in August of 2025. (5) The award for Mr. Radford reflects a one-time sign-on equity award of RSUs in connection with Mr. Radford’s hiring and appointment as Executive Vice President and Chief Financial Officer of the Company. (6) Consists of an allowance for a comprehensive annual physical, as described above. Consists of an employer 401(k) match, an annual perquisite allowance for comprehensive financial counseling and an allowance for a comprehensive annual physical as described above, and certain incremental costs (which includes a tax gross up of approximately $6,448) incurred in connection with our executive officer’s and their spouse’s or guest’s attendance at certain of the Company’s business events related to air travel, meals, activities and any other incidental event-related expenses. Consists of an employer 401(k) match, an annual perquisite allowance for comprehensive financial counseling and an allowance for a comprehensive annual physical as described above, and certain incremental costs (which includes a tax gross up of approximately $15,847) incurred in connection with our executive officer’s and their spouse’s or guest’s attendance at certain of the Company’s business events related to air travel, meals, activities and any other incidental event-related expenses (9) Consists of a severance payment of $935,062, COBRA premiums, outplacement services, an annual perquisite allowance for comprehensive financial counseling and tax planning services, and an allowance for a comprehensive annual physical, each as described above, and an employer 401(k) match.

  53. Grants of Plan-Based Awards

    Grants of Plan-Based Awards The following table shows for the fiscal year ended December 31, 2025, certain information regarding grants of plan-based awards to the NEOs:

  54. GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025

    GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025

  55. GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025

    | Named Executive Officer | Grant Date | Approval Date | Estimated Possible Payouts Under Non-Equity Incentive Plan Awards(1) | | | Estimate Future Payouts Under Equity Incentive Plan Awards(2) | | | All Other Stock Awards: Number of Units of Stock (#) | Grant Date Fair Value of Stock and Option Awards(3) ($) | | | | | Threshold ($) | Target ($) | Maximum ($) | Threshold (#) | Target (#) | Maximum (#) | | | | Randall A. Lipps | — | — | 539,124 | 1,078,248 | 2,156,496 | | — | | — | — | | | 3/15/2025 | 3/8/2025 | | — | | 39,747 | 79,494 | 158,988 | — | 2,596,274 | | | 3/15/2025 | 3/8/2025 | | — | | | — | | 79,494 | 2,623,302 | | Baird Radford | — | — | 71,784 | 143,567 | 287,134 | | — | | — | — | | | 11/15/2025 | 11/5/2025 | | — | | | — | | 32,932(4) | 1,156,572 | | Nnamdi T. Njoku | — | — | 322,500 | 645,000 | 1,290,000 | | — | | — | — | | | 3/15/2025 | 3/8/2025 | | — | | 18,705 | 37,409 | 74,818 | | 1,221,778 | | | 3/15/2025 | 3/8/2025 | | | | | | | 37,409 | 1,234,497 | | Corey J. Manley | — | — | 190,958 | 381,915 | 763,830 | | — | | — | — | | | 3/15/2025 | 3/8/2025 | | — | | 11,223 | 22,445 | 44,890 | — | 733,054 | | | 3/15/2025 | 3/8/2025 | | — | | | — | | 22,445 | 740,685 | | Nchacha E. Etta | — | — | 219,094 | 438,188 | 876,376 | | — | | — | — |

  56. GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025

    (1) For each of our NEOs, this column sets forth the threshold, target and maximum amount of each NEO’s annual cash bonus award for the year ended December 31, 2025 under the Bonus Plan, based on each NEO’s annualized salary and performance-based bonus target effective July 1, 2025 (effective August 25, 2025 for Mr. Radford). The actual cash bonus award earned for the year ended December 31, 2025, for each NEO is set forth in the Non-Equity Incentive Plan Compensation column of the 2025 Summary Compensation Table above. As such, the amounts set forth in this column do not represent additional compensation earned by the NEOs for the year ended December 31, 2025. Under Omnicell’s bonus plans, generally, if the Company does not achieve its threshold performance metrics, the NEOs are not entitled to a cash bonus award. For more information regarding the Bonus Plan and the performance-based cash bonus awards granted thereunder, please see “Elements of Compensation and 2025 Determinations - Cash Compensation Performance-Based Bonus.” The amounts reported in these columns represent PSU awards granted pursuant to the 2009 Equity Incentive Plan. Threshold amounts represent achievement of TSR performance of at least the 35th percentile but below the 50th percentile of the S&P 1000 Healthcare Index for 2025, resulting in a payout out of 50% of target PSU award. Maximum amounts represent achievement of at least the 90th percentile of the S&P 1000 Healthcare Index for 2025, resulting in a payout of 200% of target PSU award. The Company’s total stockholder return was approximately at the 60th percentile of the S&P 1000 Healthcare Index for 2025; however, as the Company’s total stockholder return for 2025 was less than zero, the percentage of the target number of PSUs eligible to be earned was capped at 100%. As a result, 100% of the target number of shares subject to the awards granted are eligible for vesting. Based on this, our NEOs earned the following amounts of PSUs: Mr. Lipps: 79,494 Mr. Njoku: 37,409; and Mr. Manley: 22,445. Vesting is contingent upon continued service. For the NEOs, other than Mr. Etta, the dollar amounts represent the grant date fair values of restricted stock units calculated in accordance with ASC Topic 718 using (i) the product of the number of shares granted and the closing market price of our common stock on the grant date for time-based RSUs and (ii) a Monte Carlo simulation model applying a multiple awards approach for PSUs. Under ASC Topic 718, the vesting condition related to the PSUs is considered a market condition and not a performance condition. Accordingly, there is no other grant date fair value other than as reflected in the table above for the NEOs that could be calculated and disclosed based on achievement of the underlying market condition. Represents RSUs granted as a one-time new hire award to Mr. Radford and which were granted pursuant to the 2009 Equity Incentive Plan. The right to receive the shares underlying the RSU grant vests as to 25% of the shares subject to the grant on November 15, 2026, with the remaining 75% of the RSUs subject to the grant vesting in equal quarterly increments on February 15, May 15, August 15, and November 15, over the three following years, subject to the NEO’s continued service.

  57. Outstanding Equity Awards at Fiscal Year End

    Outstanding Equity Awards at Fiscal Year End The following table shows certain information regarding outstanding equity awards at fiscal year-end for the NEOs for the fiscal year ended December 31, 2025.

  58. OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2025

    OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2025

  59. OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2025

    | | Option Awards | | | | | Stock Awards | | | | | | Named Executive Officer | Grant Date | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date | Grant Date | Number of Units of Stock That Have Not Vested (#) | Market Value of Units of Stock That Have Not Vested ($)(5) | Equity Incentive Plan Awards: Number of Unearned Shares That Have Not Vested (#) | Equity Incentive Plan Awards: Market Value of Unearned Shares That Have Not Vested ($)(5) | | Randall A. Lipps | 02/08/2017 | 134,160(1) | 0 | 36.70 | 02/07/2027 | 06/01/2023 | 14,688(2) | 665,366(2) | | | | | 02/06/2018 | 153,728(1) | 0 | 44.25 | 02/05/2028 | 02/27/2024 | 60,329(2) | 2,732,904(2) | | | | | 02/13/2019 | 83,845(1) | 0 | 78.91 | 02/12/2029 | 02/27/2024 | 106,196(2) | 4,810,679(2) | | | | | 02/13/2020 | 89,874(1) | 0 | 90.19 | 02/12/2030 | 03/15/2025 | 79,494(2) | 3,601,078(2) | | | | | | | | | | 03/15/2025 | | | 158,988(3)(4) | 7,202,156(3)(4) | | Nnamdi T. Njoku | | | | | | 11/15/2024 | 40,140(2) | 1,818,342(2) | | | | | | | | | | 03/15/2025 | 37,409(2) | 1,694,628(2) | | | | | | | | | | 03/15/2025 | | | 74,818(3)(4) | 3,389,256(3)(4) | | Baird Radford | | | | | | 11/15/2025 | 32,932(2) | 1,491,820(2) | | | | Corey J. Manley | | | | | | 06/01/2023 | 3,750(2) | 169,875(2) | | | | | | | | | | 02/27/2024 | 17,980(2) | 814,494(2) | | | | | | | | | | 02/27/2024 | 31,649(2) | 1,433,700(2) | | | | | | | | | | 03/15/2025 | 22,445(2) | 1,016,759(2) | | | | | | | | | | 03/15/2025 | | | 44,890(3)(4) | 2,033,517(3)(4) | | Nchacha E. Etta | | | | | | 02/27/2024 | 9,463(2) | 428,674(2) | | | | | | | | | | 02/27/2024 | 16,657(2) | 754,562(2) | | |

  60. OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2025

    (1) Stock options were granted pursuant to Omnicell’s 2009 Equity Incentive Plan. 25% of the shares subject to the option vest one year from the vesting commencement date and 1/48th of the shares vest in equal monthly installments over the following 36 months, subject to the NEO’s continued service. RSUs were granted pursuant to Omnicell’s 2009 Equity Incentive Plan. 37.5% of the shares subject to the awards granted on June 1, 2023 vest on August 15, 2024 with the remaining 62.5% of shares subject to each grant vesting in 10 equal quarterly increments on each of February 15, May 15, August 15 and November 15 over the following three years, subject to the NEO’s continued service. The shares subject to the awards granted on February 27, 2024 vest 25% on March 1, 2025 and the remaining 75% of the shares subject to the grant vesting in equal quarterly increments on May 15, August 15, November 15, and February 15 over the three following years, subject to the NEO’s continued service. 25% of the shares subject to the award granted on November 15, 2024 vest on November 15, 2025, and the remaining 75% of the shares vest in equal quarterly increments over the following three years on each of February 15, May 15, August 15 and November 15, subject to the NEO’s continued service. The shares subject to the awards granted on March 15, 2025 vest 25% on March 15, 2026 and the remaining 75% of the shares subject to the grant vesting in equal quarterly increments on May 15, August 15, November 15, and February 15 over the three following years, subject to the NEO’s continued service. 25% of the shares subject to the award granted on November 15, 2025 vest on November 15, 2026, and the remaining 75% of the shares vest in equal quarterly increments over the following three years on each of February 15, May 15, August 15 and November 15, subject to the NEO’s continued service. PSUs were granted pursuant to Omnicell’s 2009 Equity Incentive Plan. The right to receive the shares underlying the grant vest according to the description set forth in “Performance-Based Restricted Stock Unit Awards” above, with the PSUs granted on March 15, 2025 subject to performance-based vesting conditions as of December 31, 2025. In accordance with SEC disclosure rules, award amounts are reported at the maximum performance level (200% of target) based on expected performance as of December 31, 2025, for purposes of this table. With respect to the PSUs granted on March 15, 2025 earned shares, if any, will vest as follows: 25% of the shares will vest on the performance determination date, with the remaining shares vesting in 12 equal increments over three years on each of May 15, August 15, November 15 and February 15, subject to the NEO’s continued service through the applicable vesting date. (4) The Company’s total stockholder return was approximately at the 60th percentile of the S&P 1000 Healthcare Index for 2025; however, as the Company’s total stockholder return for 2025 was less than zero, the percentage of the target number of PSUs eligible to be earned was capped at 100%. As a result, approximately 100% of the target number of shares subject to the awards granted are eligible for vesting. Based on this, our NEOs earned the following amounts of PSUs: Mr. Lipps: 79,494 Mr. Njoku: 37,409; and Mr. Manley: 22,445. Vesting is contingent upon continued service. (5) The dollar amount is calculated based upon $45.30 per share, the closing price of Omnicell’s stock on December 31, 2025.

  61. Option Exercises and Stock Vested

    Option Exercises and Stock Vested The following table shows certain information regarding option exercises and stock vested with respect to the NEOs during the fiscal year ended December 31, 2025:

  62. OPTION EXERCISES AND STOCK VESTED IN FISCAL 2025

    OPTION EXERCISES AND STOCK VESTED IN FISCAL 2025

  63. OPTION EXERCISES AND STOCK VESTED IN FISCAL 2025

    | | Option Awards | | Stock Awards | | | Named Executive Officer | Number of Shares Acquired on Exercise (#) | Value Realized on Exercise(1) ($) | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting(2) ($) | | Randall A. Lipps | 28,250 | 233,568 | 147,096 | 5,128,457 | | Nnamdi T. Njoku | 0 | 0 | 13,380 | 469,286 | | Corey J. Manley | 0 | 0 | 43,081 | 1,499,850 | | Nchacha E. Etta | 0 | 0 | 65,214 | 2,226,369 |

  64. OPTION EXERCISES AND STOCK VESTED IN FISCAL 2025

    (1) The value realized on exercise is equal to the difference between the fair market value of Omnicell common stock at exercise and the option’s exercise price, multiplied by the number of shares for which the option was exercised. (2) The value realized on vesting is equal to the closing price of Omnicell common stock on the vesting date, multiplied by the number of shares that vested. Nonqualified Deferred Compensation and Pension Plans. None of our NEOs participated in nonqualified deferred compensation or pension plans during 2025.

  65. Potential Payments Upon Termination or Change of Control

    Potential Payments Upon Termination or Change of Control The amount of compensation and benefits payable to each then-serving NEO in various termination situations has been estimated in the table below, which describes the potential payments and benefits upon employment termination for each executive as if his employment had terminated as of December 31, 2025, the last business day of Omnicell’s fiscal year. See the section titled “Severance and Change of Control Arrangements” above for a description of the compensation and benefits payable to the NEOs in certain termination situations. The actual amount of compensation and benefits payable in any termination event can only be determined at the time of the termination of the NEO’s employment with us.

  66. POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

    POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

  67. POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

    | | No Change in Control Involuntary Termination without Cause | | | | | | Named Executive Officer | Cash Severance ($)(1) | Equity Award Vesting Acceleration ($)(2) | COBRA Premiums ($) | Outplacement Services(3) | Total ($) | | Randall A. Lipps(4) | 6,900,784 | 11,087,175(5) | 63,066 | 10,000 | 18,061,025 | | Baird Radford | 812,134 | 373,000 | 42,044 | 10,000 | 1,237,178 | | Nnamdi T. Njoku | 1,935,000 | 1,347,539 | 41,791 | 10,000 | 3,334,330 | | Corey J. Manley | 1,188,180 | 1,579,928 | 8,941 | 10,000 | 2,787,049 |

  68. POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

    (1) Assumes an earned bonus payout of the target bonus opportunity for the year of termination. (2) The dollar amounts in this column represents the closing price of Omnicell common stock on December 31, 2025 ($45.30) multiplied by the number of unvested RSUs and earned and outstanding PSUs, at the time of termination, that are scheduled to vest within 12 months following the date of termination, subject to the NEO’s compliance with certain customary restrictive covenants. (3) Assumes provision of outplacement services for one-year following separation based on current market data. (4) Represents the amounts to be paid under Mr. Lipps’ Employment Agreement as described in the “CEO Employment Agreement” section above. (5) The dollar amounts in this column, for equity awards granted prior to the CEO Employment Agreement, represent the closing price of Omnicell common stock on December 31, 2025 ($45.30) multiplied by the number of unvested RSUs and earned and outstanding PSUs that are scheduled to vest within 12 months following the date of termination, subject to the NEO’s compliance with certain customary restrictive covenants and, for any equity awards granted during the term of the CEO Employment Agreement, represent the closing price of Omnicell common stock on December 31, 2025 ($45.30) multiplied by the number of unvested RSUs and unvested PSUs (with respect to unearned PSUs, assumed to be satisfied at the 100% target number of PSUs) as of the termination date, subject to the NEO’s compliance with certain customary restrictive covenants.

  69. POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

    | | Change in Control Involuntary Termination without Cause or Resignation for Good Reason | | | | | | | Named Executive Officer | Cash Severance(1) ($) | Equity Award Vesting Acceleration(2) ($) | COBRA Premiums ($) | Outplacement Services(3) | Legal Fees(4) | Total ($) | | Randall A. Lipps(5) | 6,900,784 | 15,411,105 | 84,088 | 10,000 | 15,000 | 22,420,977 | | Baird Radford | 1,146,418 | 1,491,820 | 63,066 | 10,000 | 15,000 | 2,726,304 | | Corey J. Manley | 1,591,313 | 4,451,586 | 13,411 | 10,000 | 15,000 | 6,081,310 | | Nnamdi T. Njoku | 2,580,000 | 5,207,597 | 62,687 | 10,000 | 15,000 | 7,875,284 |

  70. POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

    (1) Assumes an earned bonus payout of the target bonus opportunity for the year of termination. (2) The dollar amounts in this column represents the closing price of Omnicell common stock on December 31, 2025 ($45.30) multiplied by the number of unvested RSUs and unvested PSUs (with respect to unearned PSUs, assumed to be satisfied at the 100% target number of PSUs) as of the termination date, subject to the NEO’s compliance with certain customary restrictive covenants. (3) Assumes provision of outplacement services for one-year following separation based on current market data. (4) Assumes reimbursement of $15,000 for legal fees incurred by the NEO in connection with the separation. Represents the amounts to be paid under Mr. Lipps’ Employment Agreement as described in the “CEO Employment Agreement” section above.

  71. CEO PAY RATIO

    CEO PAY RATIO Presented below is a reasonable estimate of the ratio of the annual total compensation of our CEO to the annual total compensation of the median of our other employees, calculated in a manner consistent with Item 402(u) of Regulation S-K. Given the flexibility afforded by Item 402(u) of Regulation S-K and the different methodologies that companies may use to estimate their pay ratio, the estimated ratio presented below may not be comparable to the pay ratio presented by other companies and should not be used as a basis for comparison between companies. For 2025, (i) the annual total compensation of Mr. Lipps, our President and CEO, was $7,531,852 as reflected in the 2025 Summary Compensation Table included in this proxy statement and (ii) the annual total compensation of the individual identified as our median employee was $106,853, using the same methodology required for calculating the annual total compensation of our NEOs for purposes of the 2025 Summary Compensation Table. As a result, for 2025, our estimate of the ratio of our CEO’s annual total compensation to the annual total compensation of our median employee was 70 to 1. For purposes of this disclosure, as permitted by SEC regulations, we used the same median employee as we identified for 2023 in our prior proxy statement filed during 2024 and that we used again in our proxy statement filed during 2025. We determined that overall there was no material change in our employee population or employee compensation arrangements during 2025 that would result in a significant change to our pay ratio disclosure. Historically, we have identified the median employee based employee data as of October 1. In an effort to provide a more representative number of our workforce going forward, for 2023 the Company determined to use December 31, 2023, as its determination date for identifying the median employee. As of that date, we determined that 3,711 individuals (other than our CEO) were employed by the Company and its consolidated subsidiaries globally (whether as a full-time, part-time, seasonal or temporary worker). After excluding 170 employees located in certain countries pursuant to the de minimis exemption provided under Item 402(u), the employee population that we used for purposes of determining the compensation of our median employee consisted of 3,541 individuals. The excluded countries (and their employee populations) were as follows: Austria (1), Australia (11), Belgium (1), China (25), Hong Kong (1), India (103), Lebanon (1), Mexico (9), Netherlands (1), Saudi Arabia (3), Singapore (1), Slovenia (2), Spain (3) and United Arab Emirates (8). To identify the median employee from this employee population, we calculated the total earnings of each such employee for the twelve-month period ending December 31, 2023 (with conforming adjustments for employees who joined the Company during 2023 and did not receive pay for the full period) using internal payroll data as reflected in Box 5 of Form W-2 for U.S. employees or the equivalent for non-U.S. employees. We converted compensation paid to non-U.S. employees to U.S. dollars using the applicable currency exchange rate as of December 29, 2023. For 2025, using the same median employee identified for 2023, as noted above, we calculated the median employee’s annual total compensation for fiscal year 2025 in accordance with the SEC’s requirements governing preparation of the Summary Compensation Table. We calculated the annual total compensation of the CEO for fiscal year 2025 as shown in the 2025 Summary Compensation Table.

  72. PAY VERSUS PERFORMANCE

    PAY VERSUS PERFORMANCE

  73. 2025 PAY VERSUS PERFORMANCE

    2025 PAY VERSUS PERFORMANCE

  74. 2025 PAY VERSUS PERFORMANCE

    | Year(1) | Summary Compensation Table Total for PEO ($)(2) | Compensation Actually Paid to PEO ($)(3) | Average Summary Compensation Table Total for Non-PEO NEOs ($)(2) | Average Compensation Actually Paid to Non-PEO NEOs ($)(3) | Value of Initial Fixed $100 Investment Based On:(4) | | Net Income (Loss) ($) | Non-GAAP EBITDA(6) ($) | | | | | | | Total Shareholder Return ($) | Peer Group Total Shareholder Return ($)(5) | | | | 2025 | 7,531,852 | 2,408,836 | 2,489,949 | 1,337,218 | 37.74 | 81.27 | 2,052,000 | 139,894,000 | | 2024 | 8,174,639 | 14,846,903 | 2,863,738 | 4,309,265 | 37.09 | 66.46 | 12,531,000 | 135,775,000 | | 2023 | 11,022,072 | 4,283,137 | 2,960,737 | 2,707,080 | 31.35 | 68.20 | (20,371,000) | 137,885,000 | | 2022 | 7,902,397 | (13,263,924) | 2,420,898 | (2,970,567) | 42.01 | 67.65 | 5,648,000 | 192,885,000 | | 2021 | 8,437,413 | 23,007,852 | 3,380,842 | 7,279,179 | 150.34 | 89.96 | 77,849,000 | 229,617,000 |

  75. 2025 PAY VERSUS PERFORMANCE

    (1) Mr. Lipps served as the Company’s principal executive officer for the entirety of 2021, 2022, 2023, 2024 and 2025 and the Company’s other NEOs for the applicable years were as follows: 2025: Nnamdi Njoku, Baird Radford, Corey J. Manley and Nchacha E. Etta 2024: Nnamdi Njoku, Nchacha E. Etta, and Corey J. Manley 2023: Nchacha E. Etta; Corey J. Manley; Peter J. Kuipers; Scott P. Seidelmann; and Christine Mellon. 2022: Peter J. Kuipers; Scott P. Seidelmann; Christine Mellon, Corey J. Manley and Dan S. Johnston. 2021: Peter J. Kuipers; Scott P. Seidelmann; Dan S. Johnston; and Christine Mellon. Amounts reported in this column represent (i) the total compensation reported in the Summary Compensation Table for the applicable year in the case of Mr. Lipps and (ii) the average of the total compensation reported in the Summary Compensation Table for the applicable year for the Company’s NEOs reported for the applicable year other than Mr. Lipps. (3) To calculate compensation actually paid, adjustments were made to the amounts reported in the Summary Compensation Table for the applicable year. A reconciliation of the adjustments for Mr. Lipps and for the average of the other NEOs is set forth following the footnotes to this table. (4) Pursuant to rules of the SEC, the comparison assumes $100 was invested on December 31, 2020. Historic stock price performance is not indicative of future stock price performance. (5) The TSR Peer Group consists of the NASDAQ Health Care Index, an independently prepared index that includes companies in the healthcare industry. (6) As noted in the CD&A, for 2025 the Compensation Committee determined that non-GAAP EBITDA is a core driver of the Company’s performance and stockholder value creation and, accordingly, was utilized as a component for the annual performance-based cash bonus awards. Under the annual performance-based cash bonus awards, non-GAAP EBITDA for incentive purposes represents the Company’s as-reported non-GAAP EBITDA for each quarter and is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation expenses pursuant to ASC Topic 718, as well as excluding certain other non-GAAP adjustments such as acquisition-related expenses, amortization of debt issuance costs, EnlivenHealth restructuring, RDS restructuring, legal and regulatory expenses, management severance costs, and executive transition costs.

  76. Compensation Actually Paid Adjustments

    Compensation Actually Paid Adjustments

  77. Compensation Actually Paid Adjustments

    | | | Minus | Plus | Plus/(Minus) | Plus | Plus/(Minus) | Minus | Plus | Equals | | Year | Summary Compensation Table Total ($)(a) | Grant Date Fair Value of Stock Option and Stock Awards Granted in Fiscal Year ($)(b) | Fair Value at Fiscal Year-End of Outstanding and Unvested Stock Option and Stock Awards Granted in Fiscal Year ($)(c) | Change in Fair Value of Outstanding and Unvested Stock Option and Stock Awards Granted in Prior Fiscal Years ($)(d) | Fair Value at Vesting of Stock Option and Stock Awards Granted in Fiscal Year that Vested During Fiscal Year ($)(e) | Change in Fair Value as of Vesting Date of Stock Option and Stock Awards Granted in Prior Fiscal Years for which Applicable Vesting Conditions Were Satisfied During Fiscal Year ($)(f) | Fair Value as of Prior Fiscal Year- End of Stock Option and Stock Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year ($)(g) | Changes in Fair Value to Reflect Excess Fair Value Resulting From Modifications to Stock Option and Stock Awards ($)(h) | Compensation Actually Paid | | Randall A. Lipps | | | | | | | | | | | 2025 | 7,531,852 | (5,219,576) | 8,549,580 | (3,894,102) | — | (4,558,918) | — | — | 2,408,836 | | 2024 | 8,174,639 | (6,009,274) | 13,625,167 | 222,306 | — | 96,805 | (1,262,740) | — | 14,846,903 | | 2023 | 11,022,072 | (9,174,870) | 3,031,350 | (312,629) | — | 164,437 | (447,223) | — | 4,283,137 | | 2022 | 7,902,397 | (6,699,022) | 1,328,514 | (8,414,632) | 470,595 | (7,851,777) | — | — | (13,263,924) | | 2021 | 8,437,413 | (6,001,550) | 10,175,965 | 5,991,052 | 830,085 | 3,574,887 | — | — | 23,007,852 | | Other NEOs(i) | | | | | | | | | | | 2025 | 2,489,949 | (1,271,647) | 1,982,279 | (435,577) | — | (806,046) | (621,740) | — | 1,337,218 | | 2024 | 2,863,738 | (2,118,720) | 3,750,796 | 76,171 | — | 36,350 | (299,070) | — | 4,309,265 | | 2023 | 2,960,737 | (1,404,150) | 1,408,170 | (43,870) | — | 72,948 | (402,639) | 115,884 | 2,707,080 | | 2022 | 2,420,898 | (1,879,383) | 326,852 | (1,698,012) | 131,140 | (1,607,035) | (665,026) | — | (2,970,567) | | 2021 | 3,380,842 | (2,374,967) | 3,930,801 | 1,229,594 | 363,110 | 749,800 | — | — | 7,279,179 |

  78. Compensation Actually Paid Adjustments

    (a) Represents Total Compensation as reported in the Summary Compensation Table for the indicated fiscal year. With respect to the other NEOs, amounts shown represent averages. (b) Represents the grant date fair value of the stock option and stock awards granted during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes and, in the case of awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the applicable date. (c) Represents the fair value as of the indicated fiscal year-end of the outstanding and unvested option awards and stock awards granted during such fiscal year, computed in accordance with the methodology used for financial reporting purposes and, in the case of awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the applicable date. (d) Represents the change in fair value during the indicated fiscal year of each option award and stock award that was granted in a prior fiscal year and that remained outstanding and unvested as of the last day of the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes and, for awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the last day of the fiscal year. (e) Represents the fair value at vesting of the option awards and stock awards that were granted and vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes. (f) Represents the change in fair value, measured from the prior fiscal year-end to the vesting date, of each option award and stock award that was granted in a prior fiscal year and which vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes. (g) Represents the fair value as of the last day of the prior fiscal year of the option award and stock awards that were granted in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes. (h) Represents the excess fair value, if any, of modified option or stock awards over the fair value of the original awards as of the modification and which are not otherwise reflected in the other columns in this table. (i) See footnote 1 above for the NEOs included in the average for each year. Relationship Between Pay and Performance We believe the “Compensation Actually Paid” in each of the years reported above and over the five-year cumulative period are reflective of the Compensation Committee’s emphasis on “pay-for-performance” as the “Compensation Actually Paid” fluctuated year-over-year, primarily due to the performance of our stock and the varying levels of achievement under our Bonus Plan and PSU awards. Given our executive compensation program’s emphasis on equity-based awards, the “Compensation Actually Paid” for our NEOs has been significantly impacted by changes in the performance of our stock price, as can be seen in the charts below. Performance Measures Used to Link Company Performance and Compensation Actually Paid to the NEOs Below is a list of performance measures, which in the Company’s assessment represent the most important performance measures used by the Company to link compensation actually paid to the NEOs for 2025. Please see the CD&A for further information regarding how each of these measures is used in the Company’s executive compensation program. • Non-GAAP EBITDA • Total Revenue • Total Annual Recurring Revenue • Relative Total Shareholder Return Stock Price